Truvada is a once-daily pill used for two purposes: treating HIV-1 infection and preventing it. Each tablet contains two active ingredients that work together to block HIV from copying itself inside the body. For people living with HIV, Truvada is part of a combination treatment plan. For people who don’t have HIV but are at high risk of getting it, Truvada serves as pre-exposure prophylaxis, commonly known as PrEP, reducing the risk of infection from sex by about 99% when taken as prescribed.
HIV Treatment
Truvada is FDA-approved for treating HIV-1 infection in adults and children weighing at least 17 kg (about 37 pounds). It’s never used alone for treatment. Instead, it serves as the “backbone” of a regimen that includes at least one other type of HIV medication. Most commonly, Truvada is paired with a drug from a class called integrase inhibitors, which block HIV at a different stage of its life cycle. In some situations, it may be combined with a protease inhibitor or another class of antiviral instead.
The idea behind combination therapy is to attack the virus from multiple angles at once, making it much harder for HIV to develop resistance to treatment. Truvada’s two ingredients each mimic a building block that HIV needs to copy its genetic material. When the virus tries to use these decoys, the copying process stalls and the viral chain breaks off incomplete. By pairing this approach with a drug that disrupts a completely different step, the virus has very few ways to survive and reproduce.
HIV Prevention (PrEP)
Truvada was the first medication approved for PrEP, and it remains one of the most widely prescribed options. It’s approved for at-risk adults and adolescents weighing at least 35 kg (77 pounds) who are HIV-negative. The goal is straightforward: keep enough of the drug circulating in your body so that if you’re exposed to HIV, the virus can’t establish an infection.
The numbers are striking. PrEP pills reduce the risk of getting HIV from sex by about 99% when taken daily as prescribed. For people who inject drugs, the protection is at least 74%. These figures depend heavily on adherence. Missing doses lowers the drug levels in your tissues and reduces protection significantly.
How Long It Takes to Work
Truvada doesn’t provide full protection from day one. The drug needs time to build up to effective concentrations in the tissues where HIV exposure occurs, and that timeline varies by tissue type. For receptive anal sex, PrEP pills reach maximum protection at about 7 days of daily use. For receptive vaginal sex and injection drug use, it takes roughly 21 days of daily dosing to reach full protection. During that ramp-up period, additional prevention methods like condoms are important.
What’s in Each Tablet
Each Truvada pill contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. Both ingredients belong to the same drug class. They’re synthetic versions of molecules that naturally exist in your cells, the building blocks your body uses to assemble DNA. Once you take the pill, your cells convert these ingredients into their active forms. When HIV tries to use its key enzyme to copy its genetic code, the active drug molecules get incorporated into the growing DNA chain instead of the real building blocks. This causes the chain to terminate prematurely, stopping the virus from replicating.
The two ingredients target different building blocks, so they complement each other and make it harder for HIV to find a workaround. The standard dose for both treatment and prevention is one tablet once daily, taken with or without food.
Testing Required Before Starting
Before starting Truvada for PrEP, a confirmed negative HIV test is mandatory, drawn within seven days of your first dose. This isn’t optional. Taking Truvada while unknowingly HIV-positive could lead to drug resistance, because two medications alone aren’t enough to fully suppress an active infection. You’d essentially be giving the virus a chance to learn how to evade the drugs.
Your provider will also check kidney function, since one of Truvada’s ingredients can affect the kidneys over time. A simple blood test measuring creatinine gives a picture of how well your kidneys are filtering. People with significant kidney problems may not be candidates for this particular formulation.
Hepatitis B screening is also part of the baseline workup. Both ingredients in Truvada are active against the hepatitis B virus, which sounds like a bonus, but it creates a specific risk. If you have chronic hepatitis B and later stop taking Truvada, the hepatitis B virus can rebound aggressively, causing a potentially serious flare. Knowing your hepatitis B status upfront lets your provider plan accordingly.
Side Effects and Long-Term Concerns
Most people tolerate Truvada well, especially when using it for PrEP. Early side effects, sometimes called “start-up syndrome,” can include nausea, headache, and fatigue. These typically resolve within the first few weeks.
The more meaningful concerns involve long-term use. Truvada’s tenofovir component (specifically the “disoproxil fumarate” form) has been associated with small decreases in bone mineral density and gradual changes in kidney function in some users. These effects are generally modest and reversible after stopping the medication, but they’re the reason your provider will monitor kidney labs periodically, typically every three months for PrEP users. A newer formulation called Descovy uses a different version of tenofovir that shows improved bone and kidney safety profiles, which may be preferable for people with existing risk factors in those areas.
Truvada vs. Descovy for PrEP
Descovy contains emtricitabine paired with tenofovir alafenamide, a newer form of tenofovir that delivers the drug more efficiently to cells while exposing the kidneys and bones to lower concentrations. Both medications are up to 99% effective at preventing HIV from sex when no doses are missed. The key difference is in who they’re approved for. Truvada is approved for all at-risk adults and adolescents regardless of the type of sexual exposure or route of potential transmission, including people who inject drugs. Descovy’s approval for PrEP is narrower and does not include people at risk through receptive vaginal sex, because it wasn’t studied in that population during clinical trials.
For people who inject drugs, only Truvada has data supporting its use for PrEP, with at least 74% effectiveness. Cost and insurance coverage can also differ between the two, and generic versions of Truvada are available, which often makes it the more affordable option.
Ongoing Monitoring While on PrEP
Staying on Truvada for PrEP isn’t a “set it and forget it” situation. You’ll need follow-up visits roughly every three months. At each visit, you’ll get an HIV test to confirm you’re still negative, along with kidney function labs. Screening for other sexually transmitted infections is also standard, since PrEP protects only against HIV. These regular check-ins help catch any issues early and provide an opportunity to reassess whether PrEP still fits your situation.